Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...372373374375376377378379380381382...10671068»
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Retrospective data, Journal:  Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis. (Pubmed Central) -  Feb 5, 2022   
    There was no significant correlation between the use of ixazomib and grade 3-4 neutropenia (RR = 1.46, 95% CI = 0.77-2.78, p = 0.25) or the occurrence of new primary malignant tumor (RR = 0.88, 95% CI = 0.53-1.46, p = 0.62). Additionally, more RCTs are needed for better choice of treatment regimen.
  • ||||||||||  fluticasone / Generic mfg.
    Efficacy of Budesonide versus Fluticasone in Children with Eosinophilic Esophagitis () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_2213;    
    Budesonide and fluticasone are equally effective in the treatment of EoE in children. There are no significant differences between children who respond to budesonide vs. fluticasone or between those who fail to respond to steroids.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Novel Use Of Dupilumab In A Patient With Post-Acute Sequelae of SARS-CoV-2 Infection With Severe Persistent Asthma () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_2134;    
    Blood samples of COVID-19 patients have revealed elevated levels of several cytokines and interferons, including IL-4, having a direct effect on the inflammation and damage of respiratory tracts, thus aggravating asthma symptoms. Given the significant clinical improvement shown in this case, further research warrants investigation into Dupilumab as a viable therapy for patients with PASC.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1948;    
    Given the significant clinical improvement shown in this case, further research warrants investigation into Dupilumab as a viable therapy for patients with PASC. Elderly asthma patients initiating FF/UMEC/VI in real-world clinical practice had significant clinical and economic burden and are being escalated from previous maintenance medication that likely did not adequately control their asthma.Funding: GSK (214182).
  • ||||||||||  dexamethasone / Generic mfg.
    Eosinophils are dispensable in an IL-33-dependent model of eosinophilic esophagitis (Convention Center, North Building, 100 Level, 120 Concourse) -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1675;    
    Eosinophils were dispensable for pathological features in EoE33 including epithelial hyperplasia and failure to thrive. EoE33 was steroid responsive.  We utilized a novel mouse model in which a secreted/active form of IL-33 is overexpressed in the esophagus.
  • ||||||||||  IRL201104 / Revolo Biotherap
    IRL201104, A Novel Immunomodulatory Peptide, Have A Comparable Effect To Dexamethasone In The Inflammation Associated To A Murine Model Of ARDS (Convention Center, North Building, 100 Level, 120 Concourse) -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1665;    
    IRL201104 showed an effect on neutrophilic infiltration comparable to current standard of care dexamethasone, significantly impacting several proinflammatory cytokines and chemokines that has been associated with disease severity and progression such us IL-6, TNF-α, GM-CSF or MCP-1. Unlike steroids, IRL201104 shows a clean safety profile and no immunosuppression, indicating the potential of our molecule for the treatment of ARDS patients.  IRL201104 dose-dependently reduced LPS-induced neutrophilia with the top dose effect being comparable to that of dexamethasone.
  • ||||||||||  Xhance (fluticasone propionate intranasal spray) / OptiNose
    Non-Surgical Treatment for CRSwNP () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1545;    
    Discuss the concept of shared decision-making process. Emphasize the relationship of asthma and nasal polyps as well as how the management is intertwined.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Pembrolizumab-induced Encephalopathy () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1513;    
    He was treated with IV methylprednisolone and plasmapheresis. Initially, there was some improvement, but eventually his clinical state declined and he expired
  • ||||||||||  dexamethasone / Generic mfg.
    A Rare Case of Type 2 Griscelli Syndrome in association with Hemophagocytic Lymphohistiocytosis () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1491;    
    By the third day of hospitalization, she was diagnosed with hemophagocytic lymphohistiocytosis (HLH) and started on treatment with dexamethasone. Immunology was consulted for genetic workup, which was significant for homozygous mutation in the RAB27a gene significant for autosomal recessive Griscelli syndrome type 2.
  • ||||||||||  fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
    ECMO to Treat Refractory Hypercapnia in Status Asthmaticus () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1468;    
    He was discharged with high dose fluticasone propionate, salmeterol and tiotropium, montelukast, and oral corticosteroids. He was subsequently started on Dupilumab and has not required hospitalization over the subsequent six months.
  • ||||||||||  fluticasone / Generic mfg.
    IIH and Tertiary AI Associated with Inhaled Fluticasone Discontinuation in a Pediatric Patient () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1464;    
    Ongoing research is needed to learn more about prevention and early recognition of these life-threatening phenomena.AI is due to deficient production or action of glucocorticoids with or without mineralocorticoid and adrenal androgen deficiency.8 Tertiary AI occurs after chronic exogenous steroid use, which leads to suppression of hypothalamic CRH secretion.8 It is diagnosed by low serum cortisol and ACTH, or by ACTH stimulation test.8IIH is diagnosed based on "elevated intracranial pressure with no clinical, laboratory, or radiographic evidence of responsible infection, vascular abnormality, space occupying lesion, or hydrocephalus"4. The pathogenesis of IIH is unclear, but it is associated with obesity, endocrine abnormalities, drugs (including steroid wean), viral infections, nutritional deficiencies, and genetic conditions in children.4
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Clinical, Journal:  Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2. (Pubmed Central) -  Feb 4, 2022   
    She had molecular and genetic confirmation of perforin deficiency and was started on dexamethasone and etoposide per HLH-94...The patient had a laboratory response to salvage therapy with alemtuzumab and emapalumab, but progressive neurologic decline led to withdrawal of care. This report highlights HLH foci manifest as pulmonary/renal nodules, demonstrates the utility of monitoring an array of HLH biomarkers, and suggests possible benefit of earlier salvage therapy.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Preparation and in-vitro evaluation of β-CD/HA nanocomposite as a potential carrier for hydrophobic drugs. (Pubmed Central) -  Feb 4, 2022   
    Dexamethasone (DEX) was employed as a hydrophobic model drug, which incorporated into the network of hydroxyapatite (HA)/Cyclodextrin (β-CD) nanocomposite...Release of DEX loaded β-CD/HA was measured to be around 4.6% and 18.7% in pH5.3 and pH 7.4, respectively. In conclusion, the prepared system could be a potential pH sensitive carrier for sustainable release of water-insoluble drugs.
  • ||||||||||  Onbrez (indacaterol) / Novartis
    Journal:  Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers. (Pubmed Central) -  Feb 4, 2022   
    Because of its design, the TB filter apparatus makes it possible to estimate regional deposition with inhalers directly using variable inhalation profiles without any additional equipment or changes to the experimental configuration. This method may be useful to expedite development of both innovative and generic drug products as it provides regional respiratory tract deposition estimates using fewer resources than exisiting methods.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Comparison of therapeutic effects of steroid injection by benign vocal fold lesion type. (Pubmed Central) -  Feb 4, 2022   
    In this retrospective cohort study, we included 40 condition-matched patients (8 patients per lesion) with chorditis, vocal nodules, vocal polyps, Reinke's edema (RE), or vocal scars who received similar regimens of steroid injection using a commercial preparation of triamcinolone acetonide...In subgroup analysis, VFSI was highly effective against chorditis and vocal nodules, but less effective against RE and vocal scars. Single-dose VFSI is valuable as an alternative to voice rehabilitation and laryngo-microsurgery, but higher concentrations or repeated injections are required for intractable lesions.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. (Pubmed Central) -  Feb 4, 2022   
    Male patients had higher proportions of IFN neutrophils and preferential steroid-induced immature neutrophil expansion, potentially affecting outcomes. Our single-cell atlas (see 'Data availability' section) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Role of Macrophages and Plasminogen Activator Inhibitor-1 in Delayed Bone Repair Induced by Glucocorticoids in Mice. (Pubmed Central) -  Feb 4, 2022   
    We herein investigated the roles of macrophages in glucocorticoid-induced delays in bone repair after femoral bone injury using PAI-1-deficient female mice intraperitoneally administered with dexamethasone (Dex)...It also significantly ameliorated the Dex-induced inhibition of macrophage phagocytosis at the damaged site. In conclusion, we herein demonstrated that Dex decreased the number of macrophages at the damaged site during early bone repair after femoral bone injury partly through PAI-1 and M-CSF in mice.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Preclinical, Journal:  The Effect of Long-Lasting Swimming on Rats Skeletal Muscles Energy Metabolism after Nine Days of Dexamethasone Treatment. (Pubmed Central) -  Feb 4, 2022   
    Interestingly, prolonged swimming applied after 9 days of Dex treatment significantly intensified changes induced by Dex; however, there was no difference in skeletal muscle enzymatic activities. This study shows for the first time the cumulative effect of exercise and Dex on selected elements of lipid metabolism, which seems to be essential for the patient's health due to the common use of glucocorticoids like Dex.
  • ||||||||||  hydrocortisone / Generic mfg., azithromycin / Generic mfg.
    Clinical data, Retrospective data, Journal:  Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan. (Pubmed Central) -  Feb 4, 2022   
    None of the medications whether used as monotherapy or in combination were found to have a mortality benefit. Our study highlights the desperate need for an effective drug for the management of critical COVID-19 which necessitates usage of multiple drug combinations in patients particularly Azithromycin which has long term implications for antibiotic resistance particularly in low-middle income countries.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Identification of potentially anti-COVID-19 active drugs using the connectivity MAP. (Pubmed Central) -  Feb 4, 2022   
    Four different anti-inflammatory molecules, including dexamethasone, fluorometholone and cytosporone-b, targeting the glucocorticoid receptor, cyclooxygenase, or NUR77 also came out of the analysis. These results represent a first step in the characterization of potential repositioning strategies to treat SARS-COV-2.
  • ||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
    Review, Journal:  Inhaled Pharmacotherapy for Neonates: A Narrative Review. (Pubmed Central) -  Feb 4, 2022   
    Information is given on several inhaled drugs, namely albuterol, budesonide, ipratropium bromide, sodium cromoglycate, racemic epinephrine, nitric oxide, treprostinil, iloprost, epoprostenol, colistin, rhDNase, hypertonic saline, and calfactant. A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Changes of Lacrimal Puncta by Anterior Segment Optical Coherence Tomography after Topical Combined Antibiotic and Steroid Treatment in Cases of Inflammatory Punctual Stenosis. (Pubmed Central) -  Feb 4, 2022   
    They were divided into two groups, the epiphora group one (EG1) received eye drops containing combination of antibiotics and steroids (orchadexoline eye drops, each ml contains 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg hydroxypropyl methyl cellulose, 10 mg α-tocopherol acetate (vitamin E), and 8 mg macrogol 400), 5 times daily for the first week, three times daily for the next two weeks, and one time daily for another one week...Topical combined antibiotic and steroid treatment was an effective method in treating cases of inflammatory punctual stenosis as found by monitoring of punctal parameter changes by AS-OCT. AS-OCT was found to be a useful method for evaluation of the lacrimal punctal parameters especially with different treatment modalities in epiphora cases.
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) -  Feb 4, 2022   
    P2/3,  N=412, Completed, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Recruiting --> Completed | N=820 --> 412 | Trial completion date: Feb 2022 --> Oct 2021 | Trial primary completion date: Jan 2022 --> Oct 2021